• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Al-Siddiq Waqaas

    3/14/23 4:26:54 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care
    Get the next $BTCY alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Al-Siddiq Waqaas

    (Last) (First) (Middle)
    275 SHORELINE DRIVE, SUITE 150

    (Street)
    REDWOOD CITY CA 94065

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BIOTRICITY INC. [ BTCY ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President, CEO and Chairman
    3. Date of Earliest Transaction (Month/Day/Year)
    03/12/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Option (right to purchase) $1.25 03/12/2023 A 350,000 (1) 01/27/2033 Common Stock 350,000 $0 3,549,984 D
    Option (right to purchase) $1.75 03/12/2023 A 350,000 (1) 01/27/2033 Common Stock 350,000 $0 3,899,984 D
    Option (right to purchase) $0.81 03/12/2023 A 1,000,000 (2) 01/27/2033 Common Stock 1,000,000 $0 4,899,984 D
    Explanation of Responses:
    1. Granted pursuant to the 2016 Equity Incentive Plan, with 175,000 of the Option vested January 27, 2023, and the remaining unvested Option of 175,000 will vest on January 27, 2024.
    2. Granted pursuant to the 2016 Equity Incentive Plan, with 250,000 of the Option vested January 27, 2023, and the remaining unvested Option of 20,833 will become vested and exercisable every month thereafter starting on February 27, 2023, until the Option is 100% vested.
    /s/ Waqaas Al-Siddiq 03/14/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BTCY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BTCY

    DatePrice TargetRatingAnalyst
    11/20/2023Buy → Neutral
    H.C. Wainwright
    3/7/2022$5.00Buy
    Lake Street
    11/23/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BTCY
    Financials

    Live finance-specific insights

    See more
    • Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

      FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni

      7/17/25 9:33:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Biotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18th

      Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, will host its Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18, 2025. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q

      7/15/25 5:05:00 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Biotricity Recognized by Financial Times as One of 2025's Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed

      REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times' list of The Americas' Fastest-Growing Companies 2025. This recognition highlights Biotricity's innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges. Now in its sixth year, the Financial Times, in partnership with the research firm Statista, evaluated independent companies across the Americas based on disclosed rev

      4/8/25 8:15:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BTCY
    SEC Filings

    See more
    • SEC Form 10-K filed by Biotricity Inc.

      10-K - BIOTRICITY INC. (0001630113) (Filer)

      7/15/25 5:27:01 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • SEC Form NT 10-K filed by Biotricity Inc.

      NT 10-K - BIOTRICITY INC. (0001630113) (Filer)

      6/30/25 9:20:12 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-Q/A filed by Biotricity Inc.

      10-Q/A - BIOTRICITY INC. (0001630113) (Filer)

      2/20/25 12:08:33 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BTCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

      SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)

      11/14/24 6:06:28 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Biotricity Inc.

      SC 13G - BIOTRICITY INC. (0001630113) (Subject)

      8/8/24 6:09:48 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BTCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Rosa David A

      4 - BIOTRICITY INC. (0001630113) (Issuer)

      3/15/23 4:22:52 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Al-Siddiq Waqaas

      4 - BIOTRICITY INC. (0001630113) (Issuer)

      3/14/23 4:26:54 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Ayanoglou John

      4 - BIOTRICITY INC. (0001630113) (Issuer)

      3/13/23 4:10:59 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BTCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

      FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni

      7/17/25 9:33:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Biotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18th

      Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, will host its Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18, 2025. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q

      7/15/25 5:05:00 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Biotricity Recognized by Financial Times as One of 2025's Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed

      REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times' list of The Americas' Fastest-Growing Companies 2025. This recognition highlights Biotricity's innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges. Now in its sixth year, the Financial Times, in partnership with the research firm Statista, evaluated independent companies across the Americas based on disclosed rev

      4/8/25 8:15:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BTCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Biotricity downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Biotricity from Buy to Neutral

      11/20/23 7:21:43 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Biotricity with a new price target

      Lake Street initiated coverage of Biotricity with a rating of Buy and set a new price target of $5.00

      3/7/22 9:01:18 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. initiated coverage on Biotricity with a new price target

      HC Wainwright & Co. initiated coverage of Biotricity with a rating of Buy and set a new price target of $6.00

      11/23/21 6:29:32 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care